Rep. Ritchie John Torres (D-NY) disclosed a purchase of McKesson Corporation (MCK) common stock, according to a Periodic Transaction Report filed with the U.S. House of Representatives. The transaction itself took place on January 7, 2025, and falls into the $1,001 to $15,000 range that lawmakers use to disclose trades without stating exact dollar figures.
What stands out here is not the size of the trade but the timing of the paperwork. The STOCK Act requires members of Congress to disclose transactions like this within 45 days. This report, however, was filed 206 days after the actual purchase date, well past that deadline. We note this factually as part of the record; the filing does not explain the reason for the delay, and none is speculated here.
Torres’s disclosure includes a standard explanatory note common to many congressional filings involving actively managed accounts. In his own words: ‘This investment is held within a publicly available, widely held independently managed portfolio over which I have no authority to exercise control over or influence the financial interests held by the portfolio. The assets of the portfolio are widely diversified, and all investment decisions are made solely by the independent manager, without my input or direction.’
What the Filing Shows
The report identifies the transaction as a purchase made directly by the member of Congress, not a spouse or dependent, and classifies MCK as a standard stock (ST) holding. Our internal tracking labels this a ‘congress buy’ signal, meaning it reflects new exposure to the stock rather than a sale or an option-related move. McKesson is a large pharmaceutical distribution company, and its shares are held by a wide range of institutional and individual investors, including other members of Congress.
In fact, MCK has shown up in congressional filings before. Earlier coverage on this site detailed a separate transaction involving Rep. Rick Larsen, who bought McKesson stock around the same time an insider sold shares. Seeing the same ticker surface across multiple disclosures is not unusual for widely held names like MCK, but it does help illustrate how often the same large-cap stocks appear across different lawmakers’ portfolios, regardless of party or state.
As always with these filings, the disclosure itself is a legal requirement under the STOCK Act, not an indication of any wrongdoing. Whether the trade was directed by Torres personally or executed independently within a managed account, as his filing states, the report simply adds one more data point to the public record of who in Congress is buying what, and when they eventually told us about it.